Abstract: The present invention relates to a pharmaceutical composition and a health functional food composition for preventing, alleviating or treating inflammatory diseases, including Toxoplasma gondii GRA9 protein or a gene encoding the protein as an active ingredient. The present inventors have identified the C-terminal region essential for the NLRP3-mediated mechanism of action and function of Toxoplasma gondii GRA9 in macrophages, which are host immune cells and confirmed the substantial anti-inflammatory and antibacterial effects and the antiseptic effect in vivo. Accordingly, Toxoplasma gondii GRA9 protein or a gene encoding the protein is expected to be usefully utilized in the field of prevention or treatment of inflammatory diseases caused by an abnormal NLRP3-mediated inflammatory response, including sepsis.

Abstract: The present disclosure relates to an electronic device, and more specifically, to an electronic device including a printed circuit board including a heat-generating element arranged on one surface thereof, and a heat transfer coin provided such that one surface of the heat transfer coin comes into contact with a portion of the other surface of the printed circuit board, opposite to the heat-generating element, so as to dissipate heat generated from the heat-generating element. Accordingly, the present disclosure provides an advantage of improving heat dissipation performance without increasing the thickness of the printed circuit board.

Abstract: A vehicle seat reinforcement device includes a leg portion mounted on a floor panel, a seat cushion frame slidably mounted on the leg portion, and a load reinforcing structure connected between the leg portion and the seat cushion frame, wherein when a seat belt anchorage load is transferred to the seat cushion frame, the seat cushion frame is locked to the leg portion by the load reinforcing structure.

Abstract: The present invention relates to a signal shielding apparatus and an antenna apparatus including same, and in particular, comprises a shield cover which is stacked and disposed on a printed board assembly (hereinafter, abbreviated to “PBA”), in which a plurality of signal-related components are mounted on one side thereof to prevent leakage of a signal from the plurality of signal-related components, wherein a grooved shield cover seating groove is formed in one surface of the PBA, and an insertion end insertably seated in the shield cover seating groove is integrally formed in the other surface from among one surface and the other surface of the shield cover, the other surface facing the one surface of the PBA, thereby providing advantages in that an increase in the manufacturing cost may be prevented, EMI shielding may be facilitated, and heat dissipation performance may be significantly improved.

Abstract: A vacuum cleaner is disclosed. The vacuum cleaner comprises a cleaner body, a suction nozzle, a connection pipe, a first tool assembly, a second tool assembly, and a pipe assembly. The first tool assembly is detachably fixed to a body suction port of the cleaner body and has a first suction port which communicates with the body suction port. The second tool assembly is detachably fixed to the first tool assembly and has a second suction port which communicates with the body suction port. The pipe assembly is fixed to the rear side of the connection pipe and detachably fixed to the second tool assembly. The first tool assembly, the second tool assembly, or the pipe assembly can be selectively detached from the cleaner body, and each tool (suction port) can be effectively used.

Abstract: A novel peptide analog of acylated oxyntomodulin and its uses are disclosed. A pharmaceutical composition containing the novel peptide analog is useful and effective for preventing and treating obesity or overweightness, or diabetes accompanied by obesity and overweightness. The peptide analog and a composition containing the peptide analog are superior to those of wild-type oxyntomodulin in dual agonism on GLP-1 and glucagon receptors and longer in vivo half-life. A pharmaceutical composition containing the peptide analog is effective in the treatment of metabolic diseases such as obesity and diabetes mellitus.

Abstract: A novel long-acting acylated oxyntomodulin peptide analogue having dual agonism on GLP-1 and glucagon receptors (dual GLP-1R/GlucagonR agonism) and a pharmaceutical composition including the same are disclosed. The novel long-acting acylated oxyntomodulin peptide analogue and the composition are useful for the prevention and treatment of obesity and overweight, or non-insulin-dependent diabetes accompanied by obesity and overweight. The acylated oxyntomodulin peptide analog has dual agonism for GLP-1/glucagon receptors and has an excellent increased in vivo half-life, and the pharmaceutical composition containing the same is useful for the treatment of metabolic diseases such as obesity and diabetes.

Abstract: The present invention relates to a pharmaceutical composite composition for prevention or treatment of diabetes mellitus and at least one disease selected from metabolic diseases associated therewith. The pharmaceutical composition according to the present invention exhibits excellent effects of lowering blood glucose levels, body weight, and blood lipid levels. Therefore, the composition can be advantageously used for preventing or treating diabetes mellitus and at least one disease selected from metabolic diseases associated therewith.

Abstract: A novel peptide analog of acylated oxyntomodulin and its uses are disclosed. A pharmaceutical composition containing the novel peptide analog is useful and effective for preventing and treating obesity or overweightness, or diabetes accompanied by obesity and overweightness. The peptide analog and a composition containing the peptide analog are superior to those of wild-type oxyntomodulin in dual agonism on GLP-1 and glucagon receptors and longer in vivo half-life. A pharmaceutical composition containing the peptide analog is effective in the treatment of metabolic diseases such as obesity and diabetes mellitus.

Abstract: The present invention relates to a novel peptide analog of acylated oxyntomodulin and a pharmaceutical composition comprising the same for preventing and treating obesity or overweightness, or diabetes accompanied by obesity and overweightness. The peptides are superior to those of natural oxyntomodulin in dual agonism on GLP-1 and glucagon receptors and longer in vivo half-life. A pharmaceutical composition comprising said peptides is effective in the treatment of metabolic diseases such as obesity and diabetes mellitus.

Abstract: The present invention relates to a novel peptide analog of acylated oxyntomodulin and a pharmaceutical composition comprising the same for preventing and treating obesity or overweightness, or diabetes accompanied by obesity and overweightness. The peptides are superior to those of natural oxyntomodulin in dual agonism on GLP-1 and glucagon receptors and longer in vivo half-life. A pharmaceutical composition comprising said peptides is effective in the treatment of metabolic diseases such as obesity and diabetes mellitus.

Abstract: The present invention relates to a substituted piperidines represented by following Chemical Formula 1, which have a GPR119 agonistic activity, a method for preparing the same, and a pharmaceutical composition including the same: wherein A, B, and X are defined therein.

Abstract: A refrigerator includes a door that has a front panel with an operation area to receive a touch operation of a user, a touch sensor assembly that is located rearward of the operation area and that includes sensors to generate an input signal based on the touch operation, and a sensor controller connected to the touch sensor assembly and configured to process the input signal received from the touch sensor assembly. The sensor controller is configured to determine whether the touch operation is a push operation or a release operation based on comparison of a voltage value of the processed input signal to predetermined first and second threshold voltage values.

Abstract: The present invention relates to a novel compound having a GPR119 agonistic activity, a method for preparing the same, and a pharmaceutical composition including the same as an effective component. The present invention has an effective hypoglycemic action and an effect on pancreatic beta cells, and also improves lipid metabolism which is a chronic cardiovascular risk factor, thereby having a treatment and/or prevention effect of a metabolic disease such as diabetes.

Abstract: A refrigerator includes a door that has a front panel with an operation area to receive a touch operation of a user, a touch sensor assembly that is located rearward of the operation area and that includes sensors to generate an input signal based on the touch operation, and a sensor controller connected to the touch sensor assembly and configured to process the input signal received from the touch sensor assembly. The sensor controller is configured to determine whether the touch operation is a push operation or a release operation based on comparison of a voltage value of the processed input signal to predetermined first and second threshold voltage values.

Abstract: Provided are 1-phenylpiperidin-3-one derivatives and pharmaceutically acceptable salts thereof, having cysteine protease inhibitory activity, pharmaceutical compositions containing the same as an active ingredient, and processes for the preparation thereof.

Abstract: A passenger side airbag module assembly for restraining movement of an adult or a child is disclosed. The module has an airbag module housing holding an upper airbag, and a lower airbag positioned in front of the upper airbag. The module may have either a single inflator or two inflators. Upon deployment the lower airbag has an upper surface that extends outwardly from the housing in a substantially horizontal or lower than horizontal direction and the upper airbag extends with a lower surface adjacent to the upper surface of the lower airbag; the upper airbag being deployed adjacent to the windshield of the motor vehicle and above the lower airbag.

Abstract: An airbag (10) has an inflatable chamber (301) defined by a main front panel (12) and a pair of side panels (24), (26). The airbag (10) has a vertically oriented recessed portion (20) on the main panel (12) located on a lower portion of an airbag (10), preferably vertically at or below a gas inlet passageway (30). The recessed portion (20) divides the airbag (10) into two lower lobe portions (40, 42) on each side of the recessed portion (20). Upon inflation an internal tether (50) is attached to the recessed portion (20) and is anchored at or adjacent to the gas inlet passageway (30) thereby limiting forward movement of the recessed portion (20) upon inflation. The airbag (10) is useful as a frontal airbag, particularly a passenger frontal airbag.

Abstract: Provided are 1-phenylpiperidin-3-one derivatives and pharmaceutically acceptable salts thereof, having cysteine protease inhibitory activity, pharmaceutical compositions containing the same as an active ingredient, and processes for the preparation thereof.

Abstract: The present invention relates to novel flavone/flavanone compounds or their pharmaceutically acceptable salts and process for preparation thereof for protecting gastrointestinal tracts against gastritis, ulcers and inflammatory bowel disease.